Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Payables (2016 - 2025)

Historic Payables for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $2.5 billion.

  • Teva Pharmaceutical Industries' Payables rose 1488.88% to $2.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.5 billion, marking a year-over-year increase of 1488.88%. This contributed to the annual value of $2.5 billion for FY2025, which is 1488.88% up from last year.
  • Teva Pharmaceutical Industries' Payables amounted to $2.5 billion in Q4 2025, which was up 1488.88% from $2.4 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Payables' 5-year high stood at $2.6 billion during Q4 2023, with a 5-year trough of $1.5 billion in Q3 2021.
  • For the 5-year period, Teva Pharmaceutical Industries' Payables averaged around $2.1 billion, with its median value being $2.3 billion (2023).
  • Its Payables has fluctuated over the past 5 years, first surged by 3944.95% in 2023, then crashed by 1533.44% in 2024.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Payables stood at $1.7 billion in 2021, then increased by 11.92% to $1.9 billion in 2022, then soared by 37.89% to $2.6 billion in 2023, then decreased by 15.33% to $2.2 billion in 2024, then rose by 14.89% to $2.5 billion in 2025.
  • Its Payables was $2.5 billion in Q4 2025, compared to $2.4 billion in Q3 2025 and $2.5 billion in Q2 2025.